ECSP088891A - Derivados bicíclicos como inhibidores de cetp - Google Patents

Derivados bicíclicos como inhibidores de cetp

Info

Publication number
ECSP088891A
ECSP088891A EC2008008891A ECSP088891A ECSP088891A EC SP088891 A ECSP088891 A EC SP088891A EC 2008008891 A EC2008008891 A EC 2008008891A EC SP088891 A ECSP088891 A EC SP088891A EC SP088891 A ECSP088891 A EC SP088891A
Authority
EC
Ecuador
Prior art keywords
cetp inhibitors
present
bicyclic derivatives
compounds
relates
Prior art date
Application number
EC2008008891A
Other languages
English (en)
Inventor
Eiji Kawahara
Osamu Ohmori
Ichiro Umemura
Naoko Matsuura
Masashi Kishida
Hidetomo Imase
Yuki Waki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088891A publication Critical patent/ECSP088891A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención se refiere a novedosos compuestos de la Fórmula (I): o una composición farmacéutica de los mismos, estando todas las variables definidas en el texto. La presente invención se refiere además al uso de los compuestos de la presente para el tratamiento de, o demora de progreso para superar, las enfermedades en donde esté involucrada la proteína de transferencia de colesteril-éster.
EC2008008891A 2006-05-10 2008-11-10 Derivados bicíclicos como inhibidores de cetp ECSP088891A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
ECSP088891A true ECSP088891A (es) 2008-12-30

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008891A ECSP088891A (es) 2006-05-10 2008-11-10 Derivados bicíclicos como inhibidores de cetp

Country Status (17)

Country Link
US (2) US8232403B2 (es)
EP (1) EP2024356A1 (es)
KR (1) KR101172120B1 (es)
AR (1) AR060873A1 (es)
AU (1) AU2007247385B2 (es)
CA (1) CA2650954C (es)
CL (1) CL2007001325A1 (es)
CR (1) CR10420A (es)
EC (1) ECSP088891A (es)
GT (1) GT200800242A (es)
IL (1) IL195010A0 (es)
MA (1) MA30427B1 (es)
MX (1) MX2008014284A (es)
NO (1) NO20084912L (es)
TN (1) TNSN08444A1 (es)
TW (1) TW200813009A (es)
WO (1) WO2007128568A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007919A (es) * 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質(cetp)の阻害剤としてのピリジニルアミン誘導体
KR101172120B1 (ko) * 2006-05-10 2012-08-10 노파르티스 아게 Cetp 억제제로서의 바이시클릭 유도체
JP2009536609A (ja) * 2006-05-11 2009-10-15 ノバルティス アクチエンゲゼルシャフト Cetp阻害剤としてのベンジルアミン誘導体
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP5244095B2 (ja) 2007-04-13 2013-07-24 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2383253B1 (en) 2008-11-28 2014-03-19 Kowa Company, Ltd. Method for manufacturing trans-{4-[(alkyl amino) methyl]cyclohexyl} acetic ester
EA021275B9 (ru) * 2009-09-03 2015-08-31 Байоэнердженикс Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
KR20140056258A (ko) * 2011-07-08 2014-05-09 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
MX2015006223A (es) * 2012-11-19 2015-09-25 Reddys Lab Ltd Dr Composiciones farmaceuticas de inhibidores cetp.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
TN2016000031A1 (en) 2013-07-25 2017-07-05 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
CN107406490A (zh) 2015-01-23 2017-11-28 诺华股份有限公司 具有改善的半衰期的合成apelin脂肪酸缀合物
CA3159968A1 (en) * 2019-12-11 2021-06-17 Magdalena Izabela ZAWADZKA Heterocyclic compounds as modulators of stimulator of interferon genes (sting)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451830B1 (en) * 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity
MXPA03001186A (es) * 2000-08-07 2004-04-20 Neurogen Corp Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
MXPA05010456A (es) 2003-03-28 2006-03-21 Pfizer Prod Inc Compuestos de quinolina y quinoxalina.
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP4922924B2 (ja) 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション Cetp阻害薬
CA2589322A1 (en) 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
MX2007007919A (es) * 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
EP1834490A1 (en) 2005-01-06 2007-09-19 Thomson Licensing Reducing rainbow artifacts in digital light projection systems
EP1901057A1 (en) 2005-07-07 2008-03-19 Sony Corporation Substance information acquisition method and substance information measurement device using evanescent light, and base arrangement decision method and device
WO2007008899A2 (en) 2005-07-11 2007-01-18 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
EP1981342B1 (en) * 2005-12-28 2016-11-30 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質(cetp)の阻害剤としてのピリジニルアミン誘導体
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
KR101172120B1 (ko) * 2006-05-10 2012-08-10 노파르티스 아게 Cetp 억제제로서의 바이시클릭 유도체
JP2009536609A (ja) * 2006-05-11 2009-10-15 ノバルティス アクチエンゲゼルシャフト Cetp阻害剤としてのベンジルアミン誘導体
US20100076021A1 (en) * 2006-11-15 2010-03-25 Hidetomo Imase Organic Compounds
MX2009004982A (es) * 2006-11-15 2009-05-20 Novartis Ag Derivados heterociclicos como inhibidores cetp.

Also Published As

Publication number Publication date
US8410275B2 (en) 2013-04-02
AU2007247385A1 (en) 2007-11-15
GT200800242A (es) 2009-04-29
NO20084912L (no) 2009-02-03
MA30427B1 (fr) 2009-05-04
US20090227580A1 (en) 2009-09-10
KR20090017580A (ko) 2009-02-18
AU2007247385B2 (en) 2011-07-14
CL2007001325A1 (es) 2008-07-18
EP2024356A1 (en) 2009-02-18
KR101172120B1 (ko) 2012-08-10
TW200813009A (en) 2008-03-16
WO2007128568A1 (en) 2007-11-15
AR060873A1 (es) 2008-07-16
CR10420A (es) 2009-02-02
US8232403B2 (en) 2012-07-31
IL195010A0 (en) 2009-08-03
US20120225874A1 (en) 2012-09-06
TNSN08444A1 (en) 2010-04-14
CA2650954A1 (en) 2007-11-15
MX2008014284A (es) 2008-11-18
CA2650954C (en) 2014-02-11

Similar Documents

Publication Publication Date Title
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
SV2011003855A (es) Heteroarilos sustituidos
EA201170772A1 (ru) Органические соединения
BRPI0911105A2 (pt) compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seu uso
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
UY32848A (es) Compuestos heterocíclicos de oxima
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
UY29294A1 (es) Sulfonamido-macrocíclos y sus sales como inhibidoras de tie2, composición farmacéutica que comprende estos compuestos, método de prepararlos y su uso.
UY30862A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacioon y aplicaciones
CR11639A (es) Compuesto (r)-n*6*-etil-6,7-dihidro-5h-indeno(5,6-d)tiazol-2,6-diamina y su uso como antipsicotico
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы